Last updated: 20 May 2024 at 4:20pm EST

Michael Bonney Net Worth




The estimated Net Worth of Michael W Bonney is at least $12.6 millió dollars as of 27 December 2023. Mr. Bonney owns over 30,000 units of Alnylam Pharmaceuticals Inc stock worth over $12,055,455 and over the last 13 years he sold ALNY stock worth over $0. In addition, he makes $505,707 as Independent Chairman of the Board at Alnylam Pharmaceuticals Inc.

Mr. Bonney ALNY stock SEC Form 4 insiders trading

Michael has made over 26 trades of the Alnylam Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 30,000 units of ALNY stock worth $2,893,500 on 27 December 2023.

The largest trade he's ever made was buying 71,520 units of Alnylam Pharmaceuticals Inc stock on 28 February 2019 worth over $999,850. On average, Michael trades about 2,328 units every 60 days since 2012. As of 27 December 2023 he still owns at least 46,029 units of Alnylam Pharmaceuticals Inc stock.

You can see the complete history of Mr. Bonney stock trades at the bottom of the page.





Michael Bonney biography

Michael W. Bonney is Independent Chairman of the Board of the Alnylam Pharmaceuticals, Inc. Mr. Bonney has served as the Executive Chair of Kaleido Biosciences, a biotechnology company, since June 2017. From June 2017 until August 2018, he also served as Kaleido’s Chief Executive Officer. Mr. Bonney was a Partner at Third Rock Ventures, a healthcare venture firm, from January to July 2016. Mr. Bonney previously served as the Chief Executive Officer and a member of the board of directors of Cubist Pharmaceuticals, Inc., a biopharmaceutical company (now a wholly-owned subsidiary of Merck & Co., Inc.), from June 2003 until his retirement in December 2014. From January 2002 to June 2003, he served as Cubist’s President and Chief Operating Officer. In addition, Mr. Bonney is the Chair of the board of directors of Magenta Therapeutics, Inc. and serves as a director of Celgene Corporation, Syros Pharmaceuticals, Inc. and Sarepta Therapeutics, Inc. Mr. Bonney formerly served as a director of Global Blood Therapeutics, Inc., NPS Pharmaceuticals, Inc. and Cubist.

What is the salary of Michael Bonney?

As the Independent Chairman of the Board of Alnylam Pharmaceuticals Inc, the total compensation of Michael Bonney at Alnylam Pharmaceuticals Inc is $505,707. There are 12 executives at Alnylam Pharmaceuticals Inc getting paid more, with John Maraganore having the highest compensation of $7,317,860.



How old is Michael Bonney?

Michael Bonney is 61, he's been the Independent Chairman of the Board of Alnylam Pharmaceuticals Inc since 2016. There are 9 older and 11 younger executives at Alnylam Pharmaceuticals Inc. The oldest executive at Alnylam Pharmaceuticals Inc is Phillip Sharp, 75, who is the Independent Director.

What's Michael Bonney's mailing address?

Michael's mailing address filed with the SEC is 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142.

Insiders trading at Alnylam Pharmaceuticals Inc

Over the last 20 years, insiders at Alnylam Pharmaceuticals Inc have traded over $140,068,015 worth of Alnylam Pharmaceuticals Inc stock and bought 4,419,116 units worth $1,983,132,563 . The most active insiders traders include Sanofi, Christoph H Westphal és Kevin P Starr. On average, Alnylam Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $11,181,724. The most recent stock trade was executed by Yvonne Greenstreet on 20 August 2024, trading 15,000 units of ALNY stock currently worth $1,275,000.



What does Alnylam Pharmaceuticals Inc do?

alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.



What does Alnylam Pharmaceuticals Inc's logo look like?

Alnylam Pharmaceuticals Inc logo

Complete history of Mr. Bonney stock trades at Alnylam Pharmaceuticals Inc, Global Blood Therapeutics, Sarepta Therapeutics Inc, Syros Pharmaceuticals, Bristol-Myers Squibb Co, abrdn Healthcare Investors, abrdn Life Sciences Investors, abrdn Healthcare Opportunities Fund, abrdn World Healthcare Fund, Magenta Therapeutics Inc és Kaleido Biosciences Inc

Dátum
#
Cég
Az érdekelt
Trans.
Tranzakció
Részvények száma Ár per részvény Teljes ár Részvények szíma után Forrás
27 Dec 2023 Michael W Bonney
Rendező
Opció Gyakorlat 30,000 $96.45 $2,893,500
27 Dec 2023
46,029
2 Aug 2023 Michael W Bonney
Rendező
Opció Gyakorlat 22,477 $187.01 $4,203,424
2 Aug 2023
22,477
9 Mar 2016 Michael W Bonney
Rendező
Megvenni 2,000 $58.36 $116,720
9 Mar 2016
4,000
9 Mar 2016 Michael W Bonney
Rendező
Megvenni 2,000 $58.36 $116,720
9 Mar 2016
4,000
12 May 2015 Michael W Bonney
Rendező
Megvenni 2,000 $112.16 $224,320
12 May 2015
2,000
13 Jun 2021 Michael W Bonney
Rendező
Opció Gyakorlat 902 $67.34 $60,741
13 Jun 2021
12,501
3 Jun 2021 Michael W Bonney
Rendező
Opció Gyakorlat 2,949 $64.80 $191,095
3 Jun 2021
11,599
13 Jun 2020 Michael W Bonney
Rendező
Opció Gyakorlat 1,461 $56.17 $82,064
13 Jun 2020
8,650
3 Jun 2020 Michael W Bonney
Rendező
Opció Gyakorlat 2,949 $60.21 $177,559
3 Jun 2020
7,189
4 Dec 2019 Michael W Bonney
Rendező
Megvenni 88 $58.90 $5,183
4 Dec 2019
7,189
9 Sep 2019 Michael W Bonney
Rendező
Megvenni 2,000 $86.74 $173,480
9 Sep 2019
7,051
28 Feb 2019 Michael W Bonney
Rendező
Megvenni 71,520 $13.98 $999,850
28 Feb 2019
1,008,523
17 Aug 2015 Michael W Bonney
Rendező
Megvenni 10,917 $18.35 $200,327
17 Aug 2015
10,917
28 Jul 2014 Michael W Bonney
Rendező
Megvenni 5,000 $20.00 $100,000
28 Jul 2014
5,000
9 Mar 2012 Michael W Bonney
Rendező
Megvenni 800 $13.25 $10,600
9 Mar 2012
800
9 Mar 2012 Michael W Bonney
Rendező
Megvenni 800 $13.25 $10,600
9 Mar 2012
800
9 Mar 2012 Michael W Bonney
Rendező
Megvenni 650 $15.80 $10,270
9 Mar 2012
650
9 Mar 2012 Michael W Bonney
Rendező
Megvenni 650 $15.80 $10,270
9 Mar 2012
650


Alnylam Pharmaceuticals Inc executives and stock owners

Alnylam Pharmaceuticals Inc executives and other stock owners filed with the SEC include: